Patents by Inventor Douglas Kirk Ways

Douglas Kirk Ways has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Patent number: 6486179
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: November 26, 2002
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Therapeutic treatment for cytomegalovirus infection
    Patent number: 6291446
    Abstract: A method for treating CMV infection and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione hydrochloride salt.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: September 18, 2001
    Assignee: Eli Lilly and Company
    Inventor: Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of radiation therapy
    Patent number: 6288053
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N -dimethylamino)butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: September 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Therapeutic treatment for VEGF related diseases
    Patent number: 6284751
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: September 4, 2001
    Assignee: Eli Lilly and Company
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Publication number: 20010001791
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Application
    Filed: January 10, 2001
    Publication date: May 24, 2001
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
    Patent number: 6232299
    Abstract: A method for treating neoplasms is disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″-(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation therapy.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: May 15, 2001
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Lawrence E. Stramm, Douglas Kirk Ways
  • Therapeutic treatment for renal dysfunction
    Patent number: 6225301
    Abstract: A method for treating renal dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl) ]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: May 1, 2001
    Assignees: Eli Lilly and Company
    Inventors: Douglas Kirk Ways, Richard Ernest Gilbert
  • Therapeutic treatment for VEGF related ocular diseases
    Patent number: 6114320
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: September 5, 2000
    Assignees: Eli Lilly and Company, Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Therapeutic treatment for HIV infection
    Patent number: 6107327
    Abstract: A method for treating HIV infection is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis-(3,3'-indo lyl)]-1(H)-pyrrole-2,5-dione or its acid salt.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: August 22, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapeutic treatment for asthma
    Patent number: 6103712
    Abstract: A method for treating asthma and disease conditions associated therewith is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"-(O)-4'"-(N,N-dimethylamino)-butane)-bi s-(3,3'-indoly1)]-1 (H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventor: Douglas Kirk Ways
  • Therapeutic treatment for autoimmune diseases
    Patent number: 6103713
    Abstract: Methods for inhibiting activation and/or proliferation of T cells and B cells and for treating autoimmune diseases and/or disease manifestations are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis-(3,3'-indo ly 1)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Douglas Kirk Ways, Daniel Wierda
  • Therapeutic treatment for sexual dysfunctions
    Patent number: 6093709
    Abstract: A method for treating sexual dysfunctions is disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly1)]-1(H)-pyrrole-2,5-dione, particularly its hydrochloride, or mesylate salt.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapeutic treatment for skin disorders
    Patent number: 6093740
    Abstract: A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Jirousek, Lawrence E. Stramm, Louis Vignati, Douglas Kirk Ways
  • Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
    Patent number: 5962446
    Abstract: A method for treating human T cell lymphotrophic virus type 1 infection using an isozyme selective PKC inhibitor, particularly using the isozyme selective PKC inhibitor, (S)-3,4-?N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: October 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, Douglas Kirk Ways, Lawrence E. Stramm
  • Therapeutic treatment for cardiovascular diseases
    Patent number: 5723456
    Abstract: A method for treating endothelial cell dysfunction, such as associated with cardiovascular disease are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-?N,N'-1,1'-((27"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bi s-(3,3'-indolyl)!-1(H)-pyrrole-2,5-dione hydrochloride salt.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: March 3, 1998
    Assignee: Eli Lilly & Company
    Inventors: Michael R. Jirousek, William Francis Heath, Jr., Douglas Kirk Ways, Lawrence E. Stramm